Formulations, CDSCO approvals, products, and sales of NSAID, metformin, anti-depressant/benzodiazepine, and anti-psychotic FDCs.

Numbers of FDC formulations of NSAIDs, metformin, benzodiazepines/anti-depressants, and anti-psychotics approved by the CDSCO, total formulations on the market, CDSCO-approved/unapproved formulations, formulations marketed before and after 1 May 2002, and numbers of FDC formulations available in the UK and US; numbers of FDC branded products on the market, proportions arising from approved/unapproved formulations overall, and before/after 1 May 2002; total oral drug sales in each therapeutic area, FDC sales volumes and FDC proportions of total oral drug sales, FDC sales volumes and proportions arising from approved/napproved formulations overall and before/after 1 May 2002, and FDC sales value and proportions arising from approved/unapproved formulations. FDC formulations on the market with and without a record of CDSCO approval are termed respectively “approved” and “unapproved”. Data sources: PharmaTrac; CDSCO-published list of FDC approvals 1961–February 2013.

^aExcludes products categorised as “other”.

^bIncludes all oral diabetes drugs.

^cPercent of all oral drug sales for diabetes.

^dConversion rate: INR 1 = US$0.016057.

Formulations, CDSCO approvals, products, and sales of NSAID, metformin, anti-depressant/benzodiazepine, and anti-psychotic FDCs.